Our Shareholders Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels. The latest shareholding structure of Financière de Tubize SA is available here. Shareholder Structure Investors Percent Financiere de Tubize 36% Treasury shares 2% FMR 7.5% BlackRock 6% Other Institutional Investors 34% Retail Investors 7% Wellington 3% Unidentified 5% Source Latest notifications and shareholder identification (as of January 2026), UCB underlying ownership analysis close 62% Free Float Country Percent United States 52% United Kingdom 18% France 9% Belgium 4% Rest of Europe 6% Rest of World 6% Institutional investors: Geographic distribution Shareholders' Meetings The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET. Shareholders' Meeting 2026 Shareholders' Meeting Archives Please select Shareholders meeting 2025 Shareholders meeting 2024 Shareholders meeting 2023 Shareholders meeting 2022 Shareholders meeting 2021 Shareholders meeting 2020 Shareholders meeting 2019 Shareholders meeting 2018 Shareholders meeting 2017 Select Shareholding overview Transparency notifications Share repurchase program Notification pursuant to public takeover bids legislation Consensus Estimates based on Visible Alpha consensus1 dated 30.06.2026.Estimates include 13 broker models2 collaborating with Visible Alpha. UCB FY Consensus Earnings Estimates (Average) In € million2025a H1-2026e2026e2027e2028e2029e2030e2031eNet Sales7,3883,9478,2319,33410,48811,53712,45113,040Revenue7,7414,0798,5549,63710,76111,82412,72713,331Adjusted EBIT2,0091,0602,2582,8273,5044,1514,7315,207Adjusted EBITDA2,6361,3752,9073,5464,2524,9555,57265,987Adj. EBITDA ratio34.1%33.7%34.0%36.8%39.5%41.9%43.8%44.9%Net Profit1,5588431,7712,2572,8363,4143,9394,317Core EPS (€)9.995.0610.9413.7616.9820.1522.9925.01 UCB FY Consensus Product Sales Estimates (Average) In € million2025a H1-2026e2026e2027e2028e2029e2030e2031eProduct Portfolio Cimzia1,9549021,8241,6931,5011,3301,1841,051Bimzelx2,2271,5033,3174,3585,3776,2606,9537,413Evenity*13782177210238257272264Rystiggo332207462587695785859899Zilbrysq217154347480601696766821Vimpat303126234201180164151138Keppra439197395362336311289269Briviact758244435293241212191177Fintepla427248526636726789829825Nayzilam128631341401371179787Potential New Products non-risk adjusted Dapirolizumab pegol 89192303452Staccato alprazolam 3464108147156Bepranemab 55156217363doxTM / MT1621 10224687128172211*European sales, ex-EU sales booked by Amgen/Astellas 1Disclaimer The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement. 2Contributing brokers BrokerModel dateAlphaValue02-Jun-2026Berenberg16-Mar-2026BofA12-Jun-2026Cowen04-May-2026Deutsche Bank15-May-2026Goldman Sachs29-Jun-2026Jefferies04-May-2026Morgan Stanley05-Jun-2026Redburn03-Mar-2026UBS02-Jun-2026Intron Health28-Apr-2026ODDO11-Jun-2026 All analyst contacts Dividends The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations. Year Gross Dividend (€) Net Dividend (€) 2019 1.24 0.868 2020 1.27 0.889 2021 1.30 0.91 2022 1.33 0.93 2023 1.36 0.95 2024 1.39 0.97 The Board of Directors proposes to pay a gross dividend of € 1.45 per share (gross), to be approved by the 2026 annual general meeting of the shareholders.Coupon # 29Ex-dividend: 4 May 2026Record date: 5 May 2026Payment: 6 May 2026Coupon # 29 of UCB shares is payable at € 1.015 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder. Investor Relations Team Please reach us via investor-relations@ucb.com or a specific team member: Yvonne NaughtonHead of Investor Relations +44-175-344 7521Yvonne.Naughton@ucb.com Sahar YazdianInvestor Relations Lead Lead +32 2 559 9137Sahar.Yazdian@ucb.com Diyana MishuInvestor Relations Manager +32 2 559 7446Diyana.Mishu@ucb.com Yifei (Faye) WuAssistant Assistant Assistant +32 2 559 9087Yifei.Wu@ucb.com Book a virtual meeting Send us feedback
